Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
measles, mumps, and rubella vaccine (Merck & Co.)
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intramuscular
01
Overview
The measles, mumps, and rubella (MMR) vaccine is a trivalent live-attenuated biologic product designed to confer long-term immunity against Measles morbillivirus, Mumps orthorubulavirus, and Rubella virus. It is a cornerstone of global pediatric immunization programs. Standard formulations, such as Merck's M-M-R II or GSK's Priorix, utilize specific attenuated strains: the Moraten or Schwarz strains for measles, the Jeryl Lynn or RIT 4385 strains for mumps, and the RA 27/3 strain for rubella. The 'Oka strain' mentioned in the query is a well-characterized strain of the Varicella-zoster virus (VZV) and is the primary component of varicella (chickenpox) vaccines and quadrivalent MMRV vaccines (e.g., ProQuad, Priorix-Tetra). A vaccine utilizing an 'Oka strain' for the measles component does not exist in clinical practice; the query likely conflates the trivalent MMR vaccine with the quadrivalent MMRV vaccine or misattributes the varicella strain to the measles component.
- Brand names
- TresivacTrimovax
- Other names
- MMR vaccinemeasles, mumps, and rubella virus vaccine live
Beyond the preview
Go deeper on measles, mumps, and rubella vaccine (Merck & Co.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on measles, mumps, and rubella vaccine (Merck & Co.).